Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Sclerosis, MS Clear all
Completed No phase listed Observational

Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk

NCT02440126
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Rocky Mountain MS Research Group, LLC
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Not applicable Interventional Results available

Low Load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis

NCT04633759
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Blood Flow Restriction Exercise
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Completed No phase listed Observational

JC Virus Reactivation in Multiple Sclerosis

NCT02004444
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 25, 2026, 8:45 PM EDT
Completed No phase listed Observational

Betaseron Pregnancy Registry

NCT00317564
View directory record Official record
Conditions
Birth Defects, Pregnancy Complications, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Syneos Health
Other
Eligibility
Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 25, 2026, 8:45 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Measurement and Training of Dual-Task of Gait in Persons With Multiple Sclerosis

NCT03536299
View directory record Official record
Conditions
Multiple Sclerosis, Gait Disorders, Neurologic, Cognitive Impairment
Interventions
Dual-task gait, Single-task gait
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

NCT03232073
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ponesimod
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 65 Years
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
9
States / cities
Carlsbad, California • Pomona, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 25, 2026, 8:45 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of Diet on Quality of Life in Multiple Sclerosis

NCT05007483
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BodyBio Balance Oil, Kirunal Fish Oil, BodyBio PC, Modified Paleolithic Elimination diet, Time Restricted Olive Oil Based (TROO) Ketogenic Diet, Usual diet with Dietary Guidelines for Americans Diet information
Dietary Supplement · Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 70 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Not listed No phase listed Observational

Immunodeficiency in MS

NCT04447937
View directory record Official record
Conditions
Multiple Sclerosis, Hypogammaglobulinemia, Immunodeficiency, Infection, Bacterial
Interventions
No Interventions
Other
Lead sponsor
Advanced Neurosciences Institute
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

NCT01006265
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACT-128800 Dose 1, Placebo, ACT-128800 Dose 2, ACT-128800 Dose 3
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
25
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 25, 2026, 8:45 PM EDT
Recruiting Phase 2 Interventional

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

NCT05269628
View directory record Official record
Conditions
Multiple Sclerosis, Sleep, Pain
Interventions
Cannabidiol (CBD), Tetrahydrocannabinol (THC), Placebo CBD, Placebo THC
Drug
Lead sponsor
Tiffany J. Braley, MD, MS
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

NCT04353492
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
25
States / cities
Fullerton, California • Aurora, Colorado • Newark, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

ACTH for Fatigue in Multiple Sclerosis Patients

NCT02315872
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
ACTH, Placebo
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Cullman, Alabama • Medford, Oregon • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 25, 2026, 8:45 PM EDT
Completed No phase listed Observational Results available

Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus

NCT03562975
View directory record Official record
Conditions
Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases, Autoimmune Diseases, Immune System Diseases, Primary Progressive Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 25, 2026, 8:45 PM EDT
Recruiting No phase listed Observational

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

NCT06681623
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Interventions
Ublituximab
Drug
Lead sponsor
Neurology Center of New England P.C.
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Body Weight Supported Treadmill Training in Persons With Multiple Sclerosis

NCT01992679
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Exercise group
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Urbana-Champaign, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Not applicable Interventional Results available

Prospective Randomized Endovascular Therapy in Multiple Sclerosis

NCT05380362
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Venous Angioplasty, Sham Angioplasty
Other
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 1Phase 2 Interventional

Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior

NCT01956227
View directory record Official record
Conditions
Multiple Sclerosis, Adult Disease
Interventions
Home-based exercise, Education, Exercise plus Education
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
50 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 25, 2026, 8:45 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

NCT05134441
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
IMU-838 tablets, Placebo matching IMU-838 tablets
Drug
Lead sponsor
Immunic AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
6
States / cities
Phoenix, Arizona • West Hollywood, California • Bradenton, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Recruiting Phase 1 Interventional

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

NCT06138132
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions
KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
Biological · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 4 Interventional Results available

Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue

NCT03621761
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Telephone-based Cognitive Behavioral Therapy, Modafinil
Behavioral · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced Sep 25, 2026, 8:45 PM EDT
Terminated Phase 1 Interventional Results available

Safety of Bryostatin in Patients With MS

NCT06190912
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Bryostatin 1
Drug
Lead sponsor
Robert Fox
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Recruiting Not applicable Interventional

Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

NCT06864936
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Ublituximab, Other disease modifying therapies
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Active, not recruiting No phase listed Observational

Portable Neuromodulation Stimulator Registry for People With Multiple Sclerosis

NCT06930339
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Portable Neuromodulation Stimulator (PoNS)
Device
Lead sponsor
Helius Medical Inc
Industry
Eligibility
22 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Newtown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 25, 2026, 8:45 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks

NCT00418145
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
megadose oral methylprednisolone, IV methylprednisolone
Drug
Lead sponsor
Fred Lublin
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
10
States / cities
New Brunswick, New Jersey • Brooklyn, New York • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 25, 2026, 8:45 PM EDT